Joanna E Kontaraki

List of Publications by Year
in descending order

31 papers	588 citations	686830 13 h-index	610482 24 g-index
31 all docs	31 docs citations	31 times ranked	1011 citing authors

#	Article	IF	Citations
1	Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Structural and Electrical Remodeling: From Myocardial Cytology to Cardiodiabetology. Current Vascular Pharmacology, 2022, 20, 178-188.	0.8	2
2	Long noncoding RNAs in peripheral blood mononuclear cells of hypertensive patients with heart failure with preserved ejection fraction in relation to their functional capacity. Hellenic Journal of Cardiology, 2021, 62, 473-476.	0.4	1
3	Peripheral Blood MicroRNAs as Potential Biomarkers of Myocardial Damage in Acute Viral Myocarditis. Genes, 2021, 12, 420.	1.0	10
4	Long-term prognostic value of myocardin expression levels in non-ischemic dilated cardiomyopathy. Heart and Vessels, 2021, 36, 1841-1847.	0.5	1
5	The impact of paced QRS duration on the expression of genes related to contractile function of the left ventricle in chronically paced patients from the right ventricular apex. Hellenic Journal of Cardiology, 2020, 61, 274-278.	0.4	2
6	Platelet microRNAs in hypertensive patients with and without cardiovascular disease. Journal of Human Hypertension, 2019, 33, 149-156.	1.0	15
7	MicroRNAs in Peripheral Mononuclear Cells as Potential Biomarkers in Hypertensive Patients With Heart Failure With Preserved Ejection Fraction. American Journal of Hypertension, 2018, 31, 651-657.	1.0	15
8	Bradykinin receptors gene expression in white adipose tissue in nondiabetic patients with coronary artery disease. Coronary Artery Disease, 2018, 29, 329-335.	0.3	1
9	P6655The impact of paced QRS duration on the expression of genes related to contractile function and hypertrophy of the left ventricle in chronically paced patients from the right ventricular apex. European Heart Journal, 2018, 39, .	1.0	0
10	The long nonâ€coding <scp>RNA</scp>s <i><scp>MHRT</scp></i>,<i><scp>FENDRR</scp></i> and <i><scp>CARMEN</scp></i>, their expression levels in peripheral blood mononuclear cells in patients with essential hypertension and their relation to heart hypertrophy. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 1213-1217.	0.9	20
11	Increased plateletÂalpha 2B -adrenergic receptor gene expression in well-controlled hypertensives: the effect of arterial stiffness. Journal of the American Society of Hypertension, 2017, 11, 762-768.	2.3	2
12	Low Levels of Micro<scp>RNA</scp>â€21 Are a Marker of Reduced Arterial Stiffness in Wellâ€Controlled Hypertension. Journal of Clinical Hypertension, 2017, 19, 235-240.	1.0	26
13	Comparative microRNA profiling in relation to urinary albumin excretion in newly diagnosed hypertensive patients. Journal of Human Hypertension, 2016, 30, 685-689.	1.0	11
14	Endothelial progenitor cells as markers of severity in hypertrophic cardiomyopathy. European Journal of Heart Failure, 2016, 18, 179-184.	2.9	6
15	Circulating mesenchymal stem cells in patients with hypertrophic cardiomyopathy. Cardiovascular Pathology, 2015, 24, 149-153.	0.7	10
16	Alterations in the expression of genes related to contractile function and hypertrophy of the left ventricle in chronically paced patients from the right ventricular apex. Europace, 2015, 17, 1563.1-1570.	0.7	3
17	Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. Journal of the American Society of Hypertension, 2015, 9, 802-810.	2.3	40
18	Circulating Endothelial Progenitor Cells in Hypertensive Patients With Increased Arterial Stiffness. Journal of Clinical Hypertension, 2014, 16, 295-300.	1.0	16

#	Article	IF	Citations
19	MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage. Journal of the American Society of Hypertension, 2014, 8, 368-375.	2.3	96
20	Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension. Journal of Human Hypertension, 2014, 28, 510-516.	1.0	99
21	Biochemical characterisation of Troponin C mutations causing hypertrophic and dilated cardiomyopathies. Journal of Muscle Research and Cell Motility, 2014, 35, 161-178.	0.9	23
22	Increased Mobilization of Mesenchymal Stem Cells in Patients With Essential Hypertension: The Effect of Left Ventricular Hypertrophy. Journal of Clinical Hypertension, 2014, 16, 883-888.	1.0	10
23	Blockade of platelet alpha2B-adrenergic receptors: A novel antiaggregant mechanism. International Journal of Cardiology, 2013, 168, 2561-2566.	0.8	12
24	TLR2 and TLR4 Gene Expression in Peripheral Monocytes in Nondiabetic Hypertensive Patients: The Effect of Intensive Blood Pressureâ€"Lowering. Journal of Clinical Hypertension, 2012, 14, 330-335.	1.0	35
25	Early cardiac gene transcript levels in peripheral blood mononuclear cells in patients with untreated essential hypertension. Journal of Hypertension, 2011, 29, 791-797.	0.3	19
26	Differential Effect of Telmisartan and Amlodipine on Monocyte Chemoattractant Protein-1 and Peroxisome Proliferator-Activated Receptor-Gamma Gene Expression in Peripheral Monocytes in Patients With Essential Hypertension. American Journal of Cardiology, 2011, 107, 59-63.	0.7	20
27	Myocardial gene expression alterations in peripheral blood mononuclear cells of patients with idiopathic dilated cardiomyopathy. European Journal of Heart Failure, 2010, 12, 541-548.	2.9	21
28	Arterial stiffness in hypertensives in relation to expression of angiopoietin-1 and 2 genes in peripheral monocytes. Journal of Human Hypertension, 2010, 24, 306-311.	1.0	13
29	<i>Myocardin</i> gene regulatory variants as surrogate markers of cardiac hypertrophy â€" study in a genetically homogeneous population. Clinical Genetics, 2008, 73, 71-78.	1.0	8
30	Altered expression of early cardiac marker genes in circulating cells of patients with hypertrophic cardiomyopathy. Cardiovascular Pathology, 2007, 16, 329-335.	0.7	37
31	A Functional Chromatin Domain Does Not Resist X Chromosome Inactivation: Silencing of cLys Correlates with Methylation of a Dual Promoter-Replication Origin. Molecular and Cellular Biology, 2002, 22, 4667-4676.	1.1	14